DiBenedetti D, Kosa K, Waters HC, Oberdhan D. Understanding patients' experiences with borderline personality disorder: qualitative interviews. Neuropsychiatr Dis Treat. 2023 Oct 9;19:2115-25. doi: 10.2147/NDT.S423882
Lennon RP, Zgierska AE, Miller EL, Snyder B, Keshaviah A, Hu XC, Zhou H, Van Scoy LJ. Lower intent to comply with COVID-19 public health recommendations correlates to higher disease burden in following 30 days. South Med J. 2021 Dec;114(12):744-50. doi: 10.14423/SMJ.0000000000001332
Lennon RP, Miller EL, Dong H, Rabago D, Zgierska A. Association of the US COVID-19 pandemic and attenuated influenza detection. South Med J. 2021 Jun;114(6):343. doi: 10.14423/SMJ.0000000000001254
Imagawa H, Nagar SP, Montgomery W, Nakamura T, Sato M, Davis KL. Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine. Neuropsychiatr Dis Treat. 2018 Feb 22;14:611-21. doi: 10.2147/NDT.S150261
Bullard JT, Eberth JM, Arrington AK, Adams SA, Cheng X, Salloum RG. Timeliness of treatment initiation and associated survival following diagnosis of non-small-cell lung cancer in South Carolina. South Med J. 2017 Feb;110(2):107-13. doi: 10.14423/SMJ.0000000000000601
Novick D, Montgomery W, Aguado J, Peng XM, Haro JM. Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients. Neuropsychiatr Dis Treat. 2016 Apr 11;12:795-800. doi: 10.2147/NDT.S90134
Coles T, Coon C, DeMuro C, McLeod LD, Gnanasakthy A. Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat. 2014 May 19;10:887-95. doi: 10.2147/NDT.S55220. eCollection 2014